These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10702737)

  • 21. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.
    Jackson CV; Crowe VG; Craft TJ; Sundboom JL; Grinnell BW; Bobbitt JL; Burck PJ; Quay JF; Smith GF
    Circulation; 1990 Sep; 82(3):930-40. PubMed ID: 2118431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topical heparin enhances patency in a rat model of arterial thrombosis.
    Braam MJ; Cooley BC; Gould JS
    Ann Plast Surg; 1995 Feb; 34(2):148-51; discussion 151-3. PubMed ID: 7741432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO.
    Bates ER
    Chest; 1992 Apr; 101(4 Suppl):140S-150S. PubMed ID: 1555479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
    Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
    Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
    Arnold AE; Brower RW; Collen D; van Es GA; Lubsen J; Serruys PW; Simoons ML; Verstraete M
    J Am Coll Cardiol; 1989 Sep; 14(3):581-8. PubMed ID: 2504798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The usefulness of systemic administration of recombinant human tissue-type plasminogen activator in femoral arterial thrombolysis of rabbits.
    Mino T; Suzuki J; Hayashi H
    Jpn J Pharmacol; 1989 Aug; 50(4):429-33. PubMed ID: 2476578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
    Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
    J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.
    Wall TC; Califf RM; George BS; Ellis SG; Samaha JK; Kereiakes DJ; Worley SJ; Sigmon K; Topol EJ
    J Am Coll Cardiol; 1992 Mar; 19(3):482-9. PubMed ID: 1537998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human recombinant tissue type plasminogen activator and its effect on microvascular thrombosis in the rabbit.
    Hergrueter CA; Handren J; Kersh R; May JW
    Plast Reconstr Surg; 1988 Mar; 81(3):418-24. PubMed ID: 3124145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ; Sitko GR; Mellott MJ; Nutt EM; Lehman ED; Friedman PA; Dunwiddie CT; Vlasuk GP
    Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of venous repair results using either arterial or vein grafts in a crush-avulsion injury model.
    Şirvan SS; Akgün Demir I; Irmak F; Dağdelen D; Sevim KZ; Özağarı A; Karasoy Yeşilada A
    Turk J Med Sci; 2019 Feb; 49(1):435-441. PubMed ID: 30761834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of heparin after microsurgical repair in traumatically damaged arteries.
    Zoubos AB; Soucacos PN; Seaber AV; Urbaniak JR
    Int Angiol; 1994 Dec; 13(4):336-8. PubMed ID: 7790756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithrombotic efficacy of an oral low molecular weight heparin conjugated with deoxycholic asset on microsurgical anastomosis in rats.
    Eom JS; Koh KS; Al-Hilal TA; Park JW; Jeon OC; Moon HT; Byun Y
    Thromb Res; 2010 Sep; 126(3):e220-4. PubMed ID: 20619883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of GR144053, a fibrinogen-receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tPA in the injured carotid artery of the hamster.
    Matsuno H; Kozawa O; Niwa M; Ito T; Tanabe K; Nishida M; Hayashi H; Uematsu T
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):191-7. PubMed ID: 9700979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat.
    Zhang L; Zhang ZG; Ding GL; Jiang Q; Liu X; Meng H; Hozeska A; Zhang C; Li L; Morris D; Zhang RL; Lu M; Chopp M
    Circulation; 2005 Nov; 112(22):3486-94. PubMed ID: 16316970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of nifedipine on the patency of microvascular anastomosis in rats.
    Panagiotopoulos KE; Koutsouris M; Panagiotopoulos E; Antonopoulos D; Panagiotopoulos V; Papalois A; Kepenekidis A
    Acta Chir Plast; 2008; 50(1):33-5. PubMed ID: 18686884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of recombinant hirudin to increase the patency rate of microanastomosis in a rabbit model.
    Hubbard T; Olivier T; Bacher P; Walenga JM; Galal H; Fareed J; Pifarre R
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):101-3. PubMed ID: 1772976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD; Witzke C; Colon-Hernandez P; Guerrero JL; Bloch KD; Semigran MJ
    J Am Coll Cardiol; 2006 Apr; 47(7):1471-7. PubMed ID: 16580539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.